NEWARK, Calif.--(BUSINESS WIRE)--Oraya® Therapeutics, Inc. today announced that results of its INTREPID study evaluating the safety and efficacy of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of Wet Age-Related Macular Degeneration (AMD) have now been published, on-line in the leading peer-reviewed journal Ophthalmology. The study met primary endpoints, showing that a single dose of Oraya Therapy significantly reduces the need for anti-VEGF injections for patients with Wet AMD, with a favorable safety profile one year after administration.
